West Pharmaceutical Q2 sales beats on biologics, HVP growth; raises outlook
WST•Updated outlook
- West Pharmaceutical raises full-year 2026 net sales guidance to $3.345 bln-$3.380 bln
- Company lifts full-year 2026 adjusted-diluted EPS forecast to $8.85-$9.05
- West Pharmaceutical sees Q3 2026 net sales of $820 mln-$835 mln and adjusted EPS of $2.14-$2.24
Drivers and analyst coverage
-
HVP COMPONENTS & BIOLOGICS - Co said Q2 organic sales growth was driven by High-Value Product Components, with continued strength in Biologics and a favorable mix shift from HVP upgrades including Annex 1
-
GLP-1 ELASTOMERS - Ongoing growth in GLP-1 elastomers contributed to sales gains, per CEO Eric Green
-
MARGIN EXPANSION - Strong sales growth led to operating income margin expansion compared to prior year
-
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
-
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
-
Wall Street's median 12-month price target for West Pharmaceutical Services Inc is $375.00, about 4.6% above its July 22 closing price of $358.41
